My Health News » Medical News Today - Diabetes

Feeds

164867 items (164867 unread) in 46 feeds

World Health Organization (462 unread)

• WHO news (251 unread)
• Disease Outbreak News (211 unread)

Media (128004 unread)

• Reuters Health eLine (5187 unread)
• CNN Health (1931 unread)
• NPR Health and Science (2586 unread)
• ABC News: Health (3885 unread)
• CBSnews.com: Health News (4511 unread)
• BBC Health News (3762 unread)
• CBC Health and Science News (3016 unread)
• Australia ABC News: Health (7721 unread)
• China Xinghua Health News (3974 unread)
• New York Times: Health (8872 unread)
• USATODAY.com Health - Top Stories (2939 unread)
• The Seattle Times: Health (2304 unread)
• International Herald Tribune: Health and Science (1983 unread)
• HeraldToday.com: Health (1832 unread)
• WebMD Health Headlines (4443 unread)
• MedicineNet Daily News (7011 unread)
• Medical News Today (39030 unread)
• iVillage Health (956 unread)
• Topix.net - Health (3398 unread)
• Newsvine - health (18663 unread)

Bird Flu (3515 unread)

• MSNBC.com: Bird Flu (143 unread)
• Topix.net - Bird Flu (2287 unread)
• Medical News Today - Bird Flu/Avian Flu (580 unread)
• MedicineNet Cold and Flu General (505 unread)

Diabetes (5648 unread)

• Topix.net - Diabetes (3040 unread)
• Medical News Today - Diabetes (1930 unread)
• MedicineNet Diabetes General (678 unread)

Cholesterol (2462 unread)

• Topix.net - Cholesterol (1117 unread)
• Medical News Today - Cholesterol (396 unread)
• MedicineNet Cholesterol General (949 unread)

Cancer (11808 unread)

• MSNBC.com: Cancer (527 unread)
• Topix.net - Cancer (2963 unread)
• Medical News Today - Breast Cancer News (1539 unread)
• Medical News Today - Cancer/Oncology News (5215 unread)
• MedicineNet Cancer General (1564 unread)

HIV (7247 unread)

• Topix.net - HIV/AIDS (2662 unread)
• Medical News Today - HIV/AIDS News (4342 unread)
• MedicineNet HIV General (243 unread)

Women (4402 unread)

• MSNBC.com: Women's Health (328 unread)
• Medical News Today - OBGYN News (2812 unread)
• MedicineNet Womens Health General (1262 unread)

Men (1319 unread)

• MSNBC.com: Men's Health (136 unread)
• Medical News Today - Men's health News (529 unread)
• MedicineNet Mens Health General (654 unread)

Medical News Today - Diabetes (30 unread)

• Link Between Obesity, Type 2 Diabetes And Neurodegeneration

  Posted: September 7th, 2008, 3:00am EDT

  New research from Rhode Island Hospital found that obesity and Type 2 Diabetes Mellitus (T2DM) can contribute to mild neurodegeneration with features common with Alzheimer's disease (AD) - the first study to show that obesity can cause neurodegeneration. The study appeared in the Journal of Alzheimer's Disease Volume 15:1 (September 2008) .

• CYPHER® Sirolimus-eluting Coronary Stent Comparable To Bypass Surgery In Key Safety Measures In Patients With Diabetes And Multi-Vessel Disease

  Posted: September 6th, 2008, 12:00pm EDT

  Data from the largest randomized trial of its kind performed to date indicate that the use of percutaneous coronary intervention (PCI) with the CYPHER® Sirolimus-eluting Coronary Stent was comparable to bypass surgery (coronary artery bypass grafting or CABG) in key safety endpoints in patients with multi-vessel disease and diabetes. These data were presented here recently at the European Society of Cardiology meeting.

• Mildly Infected Diabetic Foot Ulcers - Oculus Innovative Sciences Holds Successful End-of-Phase II Meeting With FDA For Microcyn(R) Technology

  Posted: September 6th, 2008, 6:00am EDT

  Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced that the company held a successful End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) on August 29, 2008. Following a review of the Phase II data on Microcyn® Technology for the treatment of mildly infected diabetic foot ulcers, the FDA agreed: - Oculus may move forward into the pivotal phase of its U.S. clinical program for Microcyn Technology.

• Nanotherapeutics Files Investigational New Drug Application For NanoDOX™ Hydrogel To Treat Lower Extremity Diabetic Ulcers

  Posted: September 6th, 2008, 4:00am EDT

  Nanotherapeutics, a privately held specialty biopharmaceutical company, announced that it has submitted its first Investigational New Drug (IND) application to the FDA for a phase IIa clinical study for its product NanoDOX™ Hydrogel, a topical doxycycline hydrogel for chronic wounds. The randomized double-blind study will assess the safety and efficacy of the product on the healing rates of non-infected diabetic ulcers of the lower extremity.

• Biodel To Report Results Of VIAject™ Pivotal Phase III Clinical Trials At EASD Conference

  Posted: September 5th, 2008, 6:00am EDT

  Biodel Inc. (Nasdaq: BIOD) announced that it will report results of its two pivotal Phase III clinical trials of VIAject™ in patients with Type 1 and Type 2 diabetes next week at the 44th Annual Meeting of the European Association for the Study of Diabetes in Rome. Two posters summarizing these results, #677 by Flacke et al.

• Physicians Eager To Increase Their First- And Second-Line Prescriptions For Januvia Over The Next Two Years For The Treatment Of Type 2 Diabetes

  Posted: September 5th, 2008, 6:00am EDT

  Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Merck's Januvia is currently prescribed most often as a third- or later-line of therapy for the treatment of type 2 diabetes.

• OSI Pharmaceuticals Initiates Clinical Development Program For Anti-Diabetes Candidate, PSN821

  Posted: September 5th, 2008, 6:00am EDT

  OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced that it has initiated a first-in-human clinical study for its G-protein coupled receptor GPR119 agonist, PSN821, which the Company is developing for the treatment of type 2 diabetes. Discovered by OSI's diabetes and obesity research team, PSN821 demonstrated both effective glucose lowering and substantial reductions of body weight in pre-clinical studies.

• Blood 'Fingerprints' For Cancer

  Posted: September 5th, 2008, 5:00am EDT

  Serum microRNAs (miRNAs) can serve as biomarkers for the detection of diseases including cancer and diabetes, according to research published online this week in Cell Research. The findings pave the way for a revolutionary non-invasive diagnostic tool. miRNAs are a class of naturally occurring small non-coding RNAs that have been linked with cancer development.

• Mechanism Of Cell Death Clarified In Oxidative Stress

  Posted: September 5th, 2008, 4:00am EDT

  Dr. Marcus Conrad of the Institute of Clinical Molecular Biology and Tumor Genetics at the Helmholtz Zentrum München has decrypted the molecular mechanism through which the death of cells is caused by oxidative stress. This knowledge opens novel perspectives to systematically explore the benefit of targeted therapeutic interventions in the cure of ageing and stress-related degenerative diseases.

• Immune Responses In Disease Monitored

  Posted: September 5th, 2008, 3:00am EDT

  A recent study (doi:10.1016/j.clim.2008.06.009) published in Clinical Immunology, the official journal of the Clinical Immunology Society (CIS), describes a new method enabling the detection of multiple parameters of single human cells. The report demonstrates the characterization of specific blood cells from an individual with type 1 diabetes, providing information about the role these cells might play in the development of the disease and during therapy.

• Battling Diabetes With Beta Cells

  Posted: September 4th, 2008, 7:00am EDT

  Affecting eight percent of America's population, diabetes can lead to blindness, kidney failure, strokes and heart disease. Thanks to Tel Aviv University researchers, a new cure - based on advances in cell therapy - may be within reach. Prof. Shimon Efrat from TAU's Sackler Faculty of Medicine, whose research group is among world leaders in beta cell expansion, has developed a way to cultivate cells derived from insulin-producing beta cells from human tissue in the laboratory.

• How Gastric Bypass Rapidly Reverses Diabetes Symptoms

  Posted: September 4th, 2008, 7:00am EDT

  A report in the September Cell Metabolism, a publication of Cell Press, offers new evidence to explain why those who undergo gastric bypass surgery often show greater control of their diabetes symptoms within days. It also helps to explain why lap-band surgery doesn't offer the same instant gratification. By studying mice that have undergone both procedures, the researchers show that changes in the intestine are the key.

• Are Diabetes And Obesity Linked To Periodontitis?

  Posted: September 3rd, 2008, 7:00am EDT

  The University of Illinois at Chicago has received a two-year federal grant to continue a study on how periodontitis, an inflammatory disease of the tissues surrounding teeth, is linked to type 2 diabetes and obesity. Dr. Keiko Watanabe of the UIC College of Dentistry has found that periodontitis accelerates the onset of insulin resistance in rats fed a high-fat diet.

• Triumphs And Tragedies In Advances In The Management Of Patients With Diabetes Mellitus:

  Posted: September 3rd, 2008, 5:00am EDT

  The need for long term studies to establish the best means of treating Diabetes, was underlined by Prof John Cleland from the University of Hull at the ESC Congress in Munich. Prof Cleland listed the latest treatment available for patients and voiced his concern about the side-effects and efficacy of available anti-diabetic drugs.

• New Stories Of Diabetes In Pregnancy

  Posted: September 2nd, 2008, 12:00pm EDT

  Diabetes UK has enhanced and extended the Pregnancy and diabetes section of its website. These webpages help to explain the diverse issues that affect women with diabetes when planning for a family and during their pregnancy. The site provides information to support expectant parents, their families and healthcare professionals.

• Come To Diabetes UK Roadshow In Leicester

  Posted: September 2nd, 2008, 8:00am EDT

  Come down and visit the Diabetes UK roadshow in Leicester on Sunday 14 September. The huge pink lorry will be in the town centre from 11am to 6pm and anyone is welcome to drop in. Free diabetes screening will be available at the roadshow throughout the day. Diabetes UK staff, including a Care Advisor and local healthcare professionals will be available throughout the day to provide information and support to anyone affected by diabetes.

• Advances In The Management Of Patients With Diabetes Mellitus

  Posted: September 2nd, 2008, 4:00am EDT

  Disappointing results of latest treatments of blood glucose which have not convincingly reduced problems, apart from sub-clinical micro-vascular disease Current drugs offer little evidence that treatment of moderate hyperglycaemia is of benefit to patients.

• Emerging Diabetes Drugs Consider Beta Cell Mass And Function As An Important Target

  Posted: September 2nd, 2008, 4:00am EDT

  The next generation of diabetes drugs still is focused on metabolic approaches, but activities to preserve or even regenerate pancreatic islet cell mass and function are gaining momentum The Business Intelligence firm La Merie S.L. reported from its most recent analysis of emerging diabetes drugs and targets that of the 59 different treatment modalities in clinical development, the majority (36) were metabolic approaches.

• DES In Diabetic Patients

  Posted: September 2nd, 2008, 3:00am EDT

  The issue of using or not using DES in patients with diabetes will be debated between Professor Wijns, who discourages DES and Professor Silber, who feels that they should be used. Diabetes is increasingly viewed as a coronary artery disease equivalent.

• SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI

  Posted: September 2nd, 2008, 3:00am EDT

  Patients with both diabetes and advanced blockages in at least three heart vessels will find good news in new findings announced from the CARDia trial, says The Society for Cardiovascular Angiography and Interventions (SCAI). The one-year findings of the new study indicate that these patients can safely choose to undergo angioplasty and stenting rather than open-heart surgery.

• Diamyd Medical: Diamyd Medical's NTDDS Technology Effective Against Diabetes Pain

  Posted: September 2nd, 2008, 3:00am EDT

  Diamyd Medical (Pink Sheets:DMYDY)(STO:DIAMB) reports that its Nerve Targeting Drug Delivery System (NTDDS) expressing enkephalin, is effective in preclinical models of diabetes pain. Dr. David Fink, published in the scientific journal "Journal of Neuroscience" that Diamyd Medical's proprietary NTDDS platform, expressing enkephalin, effectively relieves pain due to diabetes in animals.

• Newer Blood Pressure Drug Shows Promise As Alternative To ACE Inhibitors For Some Patients

  Posted: September 1st, 2008, 5:00am EDT

  Researchers in Canada working on an international study, discovered that the angiotensin-receptor blocker (ARB) telmisartan, a newer type of drug for lowering blood pressure, showed a modest reduction in cardiovascular deaths, strokes and heart attacks in patients with heart problems and diabetes who can't tolerate the standard and more widely used angiotensin-converting-enzyme (ACE) inhibitors.

• British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines

  Posted: September 1st, 2008, 4:00am EDT

  With some 20,000 UK children with Type 1 diabetes(i) about to start the new school year, new guidance from the National Institute for Health and Clinical Excellence (NICE) looks set to revolutionise the way children manage their diabetes, granting more freedom and control for their condition, by greater access to insulin pump therapy.

• CIRM Applauds The Reprogramming Of Pancreas Cells To Produce Insulin

  Posted: September 1st, 2008, 3:00am EDT

  The California Institute for Regenerative Medicine (CIRM), the state stem cell agency, issued the following statement regarding the research published in Nature by a team from Harvard that showed it is possible to take a type of adult pancreas cell that doesn't normally produce insulin and reprogram them to produce insulin. CIRM applauds the creativity and value in the research reported and shares the excitement in the promise it might hold.

• Preventing Type 2 Diabetes - Can You Help? UK

  Posted: September 1st, 2008, 3:00am EDT

  Diabetes UK is organising a ground breaking event bringing together national and international academics as well as policy makers to discuss and decide future research priorities into the prevention of Type 2 diabetes. We need people with diabetes and at risk of diabetes to bring their expertise of living with Type 2 diabetes.

• Telmisartan Modestly Reduces Major Cardiovascular Events In Patients Unable To Tolerate Ace Inhibitors (Transcend Study)

  Posted: August 31st, 2008, 7:00am EDT

  The angiotensin-receptor blocker (ARB) telmisartan should be regarded as a potential treatment for vascular disease or high-risk diabetes, in the 20% of patients who are unable to tolerate the standard treatment of angiotensin-converting enzyme (ACE) inhibitors.

• Nearly Nine Out Of Ten Patients With Type 2 Diabetes Achieve QoF HbA1c Targets With Repaglinide And Metformin

  Posted: August 31st, 2008, 3:00am EDT

  Nearly nine out of ten patients with type 2 diabetes achieved the Quality Outcomes Framework (QoF) HbA1c target of

• Amylin Pharmaceuticals And Eli Lilly Provide Context For FDA Alert For BYETTA

  Posted: August 31st, 2008, 3:00am EDT

  Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) in a conference call today provided context and additional information regarding the August 18, 2008 U.S. Food and Drug Administration (FDA) update to a prior alert for BYETTA(R) (exenatide) injection referencing pancreatitis. The companies were aware of the pancreatitis cases referenced in the alert, as well as others, and previously reported these cases to the FDA.

• CYPHER Sirolimus-eluting Coronary Stent Outperforms The Taxus® Stent In People With Diabetes

  Posted: August 30th, 2008, 5:00am EDT

  In patients with diabetes, the CYPHER® Sirolimus-eluting Coronary Stent outperformed the Taxus® Stent with significantly lower rates of in-segment restenosis (a reblockage within the stented area), target lesion revascularization (TLR; the need for another interventional procedure) and major adverse events (MACE, a composite of death, heart attack and TLR) at nine months according to clinical data appearing recently in the Journal of the American College of Cardiology.

• Why Transplanted Insulin Cells Die

  Posted: August 30th, 2008, 4:00am EDT

  New research can enhance survival of islets transplants and improve treatment of type 1 diabetes. Transplantation of insulin-producing cell islets, so-called islets of langerhans is an appealing strategy for treatment of type 1 diabetes. But it turns out that these are short-lived, and the procedure needs to be repeated.